Attached files
file | filename |
---|---|
EXCEL - IDEA: XBRL DOCUMENT - AURORA DIAGNOSTICS HOLDINGS LLC | Financial_Report.xls |
EX-31.1 - SECTION 302 CEO CERTIFICATION - AURORA DIAGNOSTICS HOLDINGS LLC | d336421dex311.htm |
EX-32.2 - SECTION 906 CFO CERTIFICATION - AURORA DIAGNOSTICS HOLDINGS LLC | d336421dex322.htm |
EX-32.1 - SECTION 906 CEO CERTIFICATION - AURORA DIAGNOSTICS HOLDINGS LLC | d336421dex321.htm |
EX-31.2 - SECTION 302 CFO CERTIFICATION - AURORA DIAGNOSTICS HOLDINGS LLC | d336421dex312.htm |
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 10-Q
(Mark One)
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2012
OR
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 333-176790
Aurora Diagnostics Holdings, LLC
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 20-4918072 | |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification Number) | |
11025 RCA Center Drive, Suite 300 Palm Beach Gardens, Florida |
33410 | |
(Address of Principal Executive Offices) | (Zip Code) |
(866) 420-5512
(Registrants Telephone Number, Including Area Code)
None
(Former Name, Former Address and Former
Fiscal Year, if Changed Since Last Report)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ¨ No x
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer | ¨ | Accelerated filer | ¨ | |||
Non-accelerated filer | x (Do not check if a smaller reporting company) | Smaller reporting company | ¨ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
Table of Contents
- ii -
Table of Contents
PART I FINANCIAL INFORMATION
Item 1. | Financial Statements. |
Aurora Diagnostics Holdings, LLC
Condensed Consolidated Balance Sheets
(in thousands)
March 31, | December 31, | |||||||
2012 | 2011 | |||||||
(unaudited) | ||||||||
Assets |
||||||||
Current Assets |
||||||||
Cash and cash equivalents |
$ | 4,874 | $ | 16,262 | ||||
Accounts receivable, net |
35,734 | 35,225 | ||||||
Prepaid expenses and other assets |
4,122 | 3,196 | ||||||
Prepaid income taxes |
1,467 | 1,144 | ||||||
Deferred tax assets |
269 | 269 | ||||||
|
|
|
|
|||||
Total current assets |
46,466 | 56,096 | ||||||
|
|
|
|
|||||
Property and equipment, net |
12,259 | 12,306 | ||||||
|
|
|
|
|||||
Other Assets: |
||||||||
Deferred debt issue costs, net |
9,313 | 9,944 | ||||||
Deposits and other noncurrent assets |
290 | 339 | ||||||
Deferred tax assetsnoncurrent |
3,035 | 3,035 | ||||||
Goodwill |
382,815 | 375,131 | ||||||
Intangible assets, net |
144,292 | 150,112 | ||||||
|
|
|
|
|||||
539,745 | 538,561 | |||||||
|
|
|
|
|||||
$ | 598,470 | $ | 606,963 | |||||
|
|
|
|
|||||
Liabilities and Members Equity |
||||||||
Current Liabilities |
||||||||
Current portion of long-term debt |
$ | 2,935 | $ | 2,910 | ||||
Current portion of fair value of contingent consideration |
20,290 | 19,270 | ||||||
Accounts payable, accrued expenses and other current liabilities |
12,830 | 14,652 | ||||||
Accrued compensation |
8,539 | 12,377 | ||||||
Accrued interest |
4,716 | 10,019 | ||||||
|
|
|
|
|||||
Total current liabilities |
49,310 | 59,228 | ||||||
Long-term debt, net of current portion |
319,056 | 313,352 | ||||||
Deferred tax liabilities, net |
20,840 | 20,840 | ||||||
Fair value of contingent consideration, net of current portion |
30,160 | 32,450 | ||||||
Other liabilities |
1,122 | 1,203 | ||||||
Members Equity |
177,982 | 179,890 | ||||||
|
|
|
|
|||||
$ | 598,470 | $ | 606,963 | |||||
|
|
|
|
See Notes to Condensed Consolidated Financial Statements.
- 1 -
Table of Contents
Condensed Consolidated Statements of Operations
Three Months Ended March 31, 2012 and 2011
Unaudited
(in thousands)
Three Months Ended | ||||||||
March 31, | ||||||||
2012 | 2011 | |||||||
Net revenue |
$ | 72,127 | $ | 62,574 | ||||
|
|
|
|
|||||
Operating costs and expenses: |
||||||||
Cost of services |
35,190 | 29,177 | ||||||
Selling, general and administrative expenses |
17,721 | 14,826 | ||||||
Provision for doubtful accounts |
4,739 | 4,349 | ||||||
Intangible asset amortization expense |
5,820 | 5,514 | ||||||
Management fees |
729 | 649 | ||||||
Acquisition and business development costs |
71 | 283 | ||||||
Change in fair value of contingent consideration |
2,247 | 1,702 | ||||||
|
|
|
|
|||||
Total operating costs and expenses |
66,517 | 56,500 | ||||||
|
|
|
|
|||||
Income from operations |
5,610 | 6,074 | ||||||
|
|
|
|
|||||
Other income (expense): |
||||||||
Interest expense |
(8,163 | ) | (8,099 | ) | ||||
Other income |
4 | 15 | ||||||
|
|
|
|
|||||
Total other expense, net |
(8,159 | ) | (8,084 | ) | ||||
|
|
|
|
|||||
Loss before income taxes |
(2,549 | ) | (2,010 | ) | ||||
Benefit for income taxes |
(465 | ) | (47 | ) | ||||
|
|
|
|
|||||
Net loss |
$ | (2,084 | ) | $ | (1,963 | ) | ||
|
|
|
|
See Notes to Condensed Consolidated Financial Statements.
- 2 -
Table of Contents
Condensed Consolidated Statements of Cash Flows
Three Months Ended March 31, 2012 and 2011
Unaudited
(in thousands)
2012 | 2011 | |||||||
Cash Flows From Operating Activities |
||||||||
Net loss |
$ | (2,084 | ) | $ | (1,963 | ) | ||
Adjustments to reconcile net loss to net cash provided by operating activities: |
||||||||
Depreciation and amortization |
6,990 | 6,433 | ||||||
Amortization of deferred debt issue costs |
529 | 476 | ||||||
Amortization of original issue discount on debt |
72 | 71 | ||||||
Deferred income taxes |
| (2,031 | ) | |||||
Equity compensation costs |
133 | | ||||||
Change in fair value of contingent consideration |
2,247 | 1,702 | ||||||
Loss on disposal of property |
(3 | ) | | |||||
Changes in assets and liabilities, net of working capital acquired in business combinations: |
||||||||
(Increase) decrease in: |
||||||||
Accounts receivable |
(509 | ) | 323 | |||||
Prepaid income taxes |
(323 | ) | 1,287 | |||||
Prepaid expenses |
(926 | ) | (278 | ) | ||||
Increase (decrease) in: |
||||||||
Accounts payable, accrued expenses and other current liabilities |
(1,660 | ) | 418 | |||||
Accrued compensation |
(3,838 | ) | 863 | |||||
Accrued interest |
(5,303 | ) | 5,454 | |||||
|
|
|
|
|||||
Net cash (used in) provided by operating activities |
(4,675 | ) | 12,755 | |||||
|
|
|
|
|||||
Cash Flows From Investing Activities |
||||||||
Purchase of property and equipment |
(940 | ) | (961 | ) | ||||
Increase in deposits and other noncurrent assets |
49 | 182 | ||||||
Payment of contingent notes |
(11,201 | ) | (9,731 | ) | ||||
Businesses acquired, net of cash acquired |
| 650 | ||||||
|
|
|
|
|||||
Net cash used in investing activities |
(12,092 | ) | (9,860 | ) | ||||
|
|
|
|
|||||
Cash Flows From Financing Activities |
||||||||
Payments of capitalized lease obligations |
(23 | ) | (16 | ) | ||||
Net borrowings under revolver |
5,500 | | ||||||
Payment of debt issuance costs |
(141 | ) | (687 | ) | ||||
Payment of public offering costs |
| (200 | ) | |||||
Contributions from members |
43 | | ||||||
|
|
|
|
|||||
Net cash provided by (used in) financing activities |
5,379 | (903 | ) | |||||
|
|
|
|
|||||
Net (decrease) increase in cash |
(11,388 | ) | 1,992 | |||||
Cash and cash equivalents, beginning |
16,262 | 39,941 | ||||||
|
|
|
|
|||||
Cash and cash equivalents, ending |
$ | 4,874 | $ | 41,933 | ||||
|
|
|
|
(Continued)
- 3 -
Table of Contents
Condensed Consolidated Statements of Cash Flows (Continued)
Three Months Ended March 31, 2012 and 2011
Unaudited
(in thousands)
2012 | 2011 | |||||||
Supplemental Disclosures of Cash Flow Information |
||||||||
Cash interest payments |
$ | 12,817 | $ | 1,987 | ||||
|
|
|
|
|||||
Cash tax payments, including member tax distributions |
$ | 197 | $ | 352 | ||||
|
|
|
|
|||||
Supplemental Schedule of Noncash Investing and Financing Activities |
||||||||
Fair value of contingent consideration issued in acquisitions |
$ | | $ | 7,570 | ||||
|
|
|
|
|||||
Capital lease obligations |
$ | 180 | $ | 16 | ||||
|
|
|
|
See Notes to Condensed Consolidated Financial Statements.
- 4 -
Table of Contents
Note 1. Nature of Business and Significant Accounting Policies
Nature of business
Aurora Diagnostics Holdings, LLC and subsidiaries (the Company) was organized in the State of Delaware as a limited liability company on June 2, 2006 to operate as a diagnostic services company. The Companys practices provide physician-based general anatomic and clinical pathology, dermatopathology, molecular diagnostic services and other esoteric testing services to physicians, hospitals, clinical laboratories and surgery centers. The Companys operations consist of one reportable segment.
The Company operates in a highly regulated industry. The manner in which licensed physicians can organize to perform and bill for medical services is governed by state laws and regulations. Businesses like the Company often are not permitted to employ physicians or to own corporations that employ physicians or to otherwise exercise control over the medical judgments or decisions of physicians.
In states where the Company is not permitted to directly own a medical services provider or for other commercial reasons, it performs only non-medical administrative and support services, does not represent to the public or its clients that it offers medical services and does not exercise influence or control over the practice of medicine. In those states, the Company conducts business through entities that it controls, and it is these affiliated entities that employ the physicians who practice medicine. In such states, the Company generally enters into a contract that restricts the owner of the affiliated entity from transferring their ownership interests in the affiliated entity and otherwise provides the Company or its designee with a controlling voting or financial interest in the affiliated entity and its laboratory operations. This controlling financial interest generally is obtained pursuant to a long-term management services agreement between the Company and the affiliated entity. Under the management services agreement, the Company exclusively manages all aspects of the operation other than the provision of medical services. Generally, the affiliated entity has no operating assets because the Company acquired all of its operating assets at the time it acquired the related laboratory operations. In accordance with the relevant literature, these affiliated entities are included in the condensed consolidated financial statements of Aurora Diagnostics Holdings, LLC.
The accompanying consolidated balance sheet as of December 31, 2011, which was derived from the audited financial statements as of December 31, 2011 of Aurora Diagnostics Holdings, LLC, and the accompanying unaudited condensed consolidated financial statements as of and for the three month periods ended March 31, 2012 and March 31, 2011 have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial reporting. Accordingly, they do not include all of the information and related footnotes that would normally be required by accounting principles generally accepted in the United States of America for complete financial reporting. These unaudited condensed consolidated financial statements should be read in conjunction with the Companys audited financial statements for the year ended December 31, 2011.
The accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of a normal and recurring nature) that management considers necessary for a fair statement of financial information for the interim periods. Interim results are not necessarily indicative of the results that may be expected for the remainder of the year ending December 31, 2012.
Recent Accounting Standards Updates
In May 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2011-04 Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. The standard revises guidance for fair value measurement and expands the disclosure requirements. The Company adopted ASU 2011-04 effective January 1, 2012. The adoption of ASU 2011-04 did not have a material impact on the Companys financial position, results of operations or cash flows.
- 5 -
Table of Contents
Note 1. Nature of Business and Significant Accounting Policies (Continued)
In June 2011, the FASB issued ASU 2011-05 Presentation of Comprehensive Income which requires an entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income, or in two separate but consecutive statements. ASU 2011-05 eliminates the option to present components of other comprehensive income as part of the statement of equity. In December 2011, the FASB issued ASU No. 2011-12, Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05 which defers the requirement within ASU 2011-05 to present reclassification adjustments from other comprehensive income to net income on the face of the financial statements pending further deliberation by the FASB. These ASUs require retrospective application and are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with early adoption permitted. The Company adopted ASU 2011-05 effective January 1, 2012. The adoption of ASU 2011-05 did not have a material impact on the Companys financial position, results of operations or cash flows.
In July 2011, the FASB issued ASU 2011-07, Health Care Entities (Topic 954): Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities, which requires certain health care entities to present the provision for bad debts related to patient service revenue as a deduction from patient service revenue in the statement of operations rather than as an operating expense. This ASU is effective for public companies with fiscal years and interim periods within those fiscal years beginning after December 15, 2011. Additional disclosures relating to a companys sources of patient revenue and its allowance for doubtful accounts related to patient accounts receivable will also be required. The Company adopted ASU 2011-07 effective January 1, 2012. The adoption of ASU 2011-07 did not have a material impact on the Companys financial position, results of operations or cash flows.
In September 2011, the FASB issued ASU No. 2011-08, Intangibles Goodwill and Other (Topic 350) Testing Goodwill for Impairment. ASU 2011-08 permits an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If an entity determines it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then it is required to perform the two-step impairment test. If an entity concludes otherwise, then the two-step impairment test is not required. The Company adopted ASU 2011-08 for its annual goodwill impairment tests performed as of September 30, 2011 and performed qualitative analyses to assess the likelihood of impairment at its reporting units. The Companys assessment considered various factors, including the results of the impairment analyses performed as of September 30, 2010, changes in the carrying amount of net assets since September 30, 2010, managements expectations of future performance, historical financial results and trends, changes in interest rates and other market conditions and other factors affecting reporting unit fair values. The Company also considered each reporting units performance in relation to previous projections, the economic outlook for the healthcare services industry and various other factors during the testing process, including hospital and physician contract changes, local market developments, changes in third-party payor payments, and other publicly available information. Based on its assessment, the Company determined it was more likely than not that the fair value exceeded the carrying value for four of its twenty reporting units. For these four reporting units the Company did not perform the two step impairment testing.
In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 220) Disclosures About Offsetting Assets and Liabilities which creates new disclosure requirements about the nature of an entitys rights of offset associated with its financial instruments and derivative instruments. ASU No. 2011-11 requires retrospective application, and it is effective for fiscal years, and interim periods within those years, beginning on or after January 1, 2013. We are currently evaluating the impact, if any, the adoption of ASU 2011-11 will have on our financial position, results of operations or cash flows.
- 6 -
Table of Contents
Note 2. Acquisitions
2011 Acquisitions
During 2011, the Company acquired four pathology practices. On January 1, 2011, the Company acquired 100% of the equity of two pathology practices for an aggregate cash purchase price of $36.9 million. These acquisitions were funded on December 31, 2010 and therefore, the cash paid totaling $36.9 million was included in Deposits and other non-current assets as of December 31, 2010. On June 2, 2011, the Company acquired 100% of the equity of a third pathology practice for a cash purchase price of $14.7 million. On August 1, 2011, the Company acquired substantially all of the assets of a fourth pathology practice for an aggregate cash purchase price of $26.5 million. In each of the transactions the Company issued contingent consideration payable over three to five years based on the acquirees future performance. The total acquisition date fair value of the contingent consideration issued for the 2011 acquisitions was $20.5 million. The Company funded the cash portion of the January 1, 2011 and June 2, 2011 acquisitions using a portion of the proceeds from the Senior Notes offering on December 20, 2010. The Company funded the cash portion of the August 1, 2011 acquisition using cash on hand, as well as $14.0 million drawn on its revolving credit facility.
Intangible assets acquired as the result of a business combination are recognized at fair value as an asset apart from goodwill if the asset arises from contractual or other legal rights or if it is separable. The Companys intangible assets, which principally consist of the fair value of customer relationships, health care facility agreements and non-competition agreements acquired in connection with the acquisition of diagnostic companies, are capitalized and amortized on the straight-line method over their useful life, which generally ranges from 4 to 18 years. Approximately $33.3 million of tax deductible goodwill was recorded related to the 2011 acquisitions.
Contingent Consideration
In connection with its acquisitions, the Company has agreed to pay additional consideration in future periods based upon the attainment of stipulated levels of operating earnings by each of the acquired entities, as defined in their respective agreements. For all acquisitions prior to January 1, 2009, the Company does not accrue contingent consideration obligations prior to the attainment of the objectives and the amount owed becomes fixed and determinable. The Company paid consideration under contingent notes related to acquisitions completed prior to January 1, 2009 of $7.7 million and $9.2 million for the three months ended March 31, 2012 and 2011, respectively. For the three month periods ended March 31, 2012 and 2011, the Company paid consideration under contingent notes related to acquisitions completed subsequent to January 1, 2009 of $3.5 million and $0.5 million, respectively.
As of March 31, 2012, assuming the acquired practices achieve the maximum level of stipulated operating earnings, the maximum principal amount of contingent consideration payable over the next two years is approximately $56.3 million for acquisitions completed prior to January 1, 2009 and $98.6 million for acquisitions completed subsequent to January 1, 2009. A lesser amount will be paid if the practices earnings are below the maximum level of stipulated earnings or no payments will be made if the practices do not achieve the minimum level of stipulated earnings as outlined in their respective agreements. Any such payments in the future for acquisitions completed prior to January 1, 2009 would be accounted for as additional purchase price and increase goodwill. For acquisitions completed subsequent to January 1, 2009, future payments will be reflected in the change in the fair value of the contingent consideration. The total fair value of the contingent consideration reflected in the accompanying consolidated condensed balance sheets as of March 31, 2012 and December 31, 2011 is $50.5 million and $51.7 million, respectively.
- 7 -
Table of Contents
Note 2. Acquisitions (Continued)
Pro-forma information (unaudited)
The following unaudited pro forma information presents the consolidated results of the Companys operations and the results of the two acquisitions completed after January 1, 2011 for the three months ended March 31, 2011, after giving effect to amortization, depreciation, interest, income tax, and the reduced level of certain specific operating expenses (primarily compensation and related expenses attributable to former owners) as if the acquisitions had been consummated on January 1, 2011. Such unaudited pro forma information is based on historical unaudited financial information with respect to the 2011 acquisitions and does not include operational or other changes which might have been effected by the Company. The unaudited pro forma information for the three months ended March 31, 2011 presented below is for illustrative purposes only and is not necessarily indicative of results which would have been achieved or results which may be achieved in the future (in thousands):
Pro Forma | ||||
Three Months Ended | ||||
March 31, 2011 | ||||
Net revenue |
$ | 68,036 | ||
|
|
|||
Net loss |
$ | (1,227 | ) | |
|
|
For the three months ended March 31, 2012, the two acquisitions completed after January 1, 2011 contributed a total of $7.3 million in net revenue and $1.4 million in net earnings, excluding intercompany charges eliminated in consolidation.
Note 3. Accounts Receivable
Accounts receivable consist of the following as of March 31, 2012 and December 31, 2011 (in thousands):
March 31, 2012 | December 31, 2011 | |||||||
Accounts receivable |
$ | 54,114 | $ | 52,747 | ||||
Less: Allowance for doubtful accounts |
(18,380 | ) | (17,522 | ) | ||||
|
|
|
|
|||||
Accounts receivable, net |
$ | 35,734 | $ | 35,225 | ||||
|
|
|
|
Note 4. Goodwill and Intangible Assets
The following table presents adjustments to goodwill during the three months ended March 31, 2012 and the year ended December 31, 2011 (in thousands):
March 31, 2012 | December 31, 2011 | |||||||
Goodwill, beginning of period |
$ | 375,131 | $ | 329,199 | ||||
Acquisitions |
| 52,480 | ||||||
Contingent notes* |
7,684 | 12,654 | ||||||
Goodwill impairment |
| (19,202 | ) | |||||
|
|
|
|
|||||
Goodwill, end of period |
$ | 382,815 | $ | 375,131 | ||||
|
|
|
|
* | Related to acquisitions completed prior to January 1, 2009. |
- 8 -
Table of Contents
Note 4. Goodwill and Intangible Assets (Continued)
For the three months ended March 31, 2012 and 2011, the Company recorded amortization expense of $5.8 million and $5.5 million, respectively, related to its intangible assets. The Companys balances for intangible assets as of March 31, 2012 and December 31, 2011 and the related accumulated amortization are set forth in the table below (in thousands):
Weighted Average | March 31, 2012 | |||||||||||||||
Range | Amortization | Accumulated | ||||||||||||||
(Years) |
Period (Years) | Cost | Amortization | Net | ||||||||||||
Amortizing intangible assets: |
||||||||||||||||
Customer relationships |
4 10 | 9 | $ | 152,249 | $ | (55,371 | ) | $ | 96,878 | |||||||
Health care facility agreements |
4 18 | 14 | 60,716 | (15,598 | ) | 45,118 | ||||||||||
Noncompete agreements |
4 5 | 5 | 5,678 | (3,382 | ) | 2,296 | ||||||||||
|
|
|
|
|
|
|||||||||||
Total intangible assets |
$ | 218,643 | $ | (74,351 | ) | $ | 144,292 | |||||||||
|
|
|
|
|
|
Weighted Average | December 31, 2011 | |||||||||||||||
Range | Amortization | Accumulated | ||||||||||||||
(Years) |
Period (Years) | Cost | Amortization | Net | ||||||||||||
Amortizing intangible assets: |
||||||||||||||||
Customer relationships |
5 10 | 9 | $ | 152,249 | $ | (50,736 | ) | $ | 101,513 | |||||||
Health care facility agreements |
4 18 | 14 | 60,716 | (14,631 | ) | 46,085 | ||||||||||
Noncompete agreements |
4 5 | 5 | 5,678 | (3,164 | ) | 2,514 | ||||||||||
|
|
|
|
|
|
|||||||||||
Total intangible assets |
$ | 218,643 | $ | (68,531 | ) | $ | 150,112 | |||||||||
|
|
|
|
|
|
As of March 31, 2012, estimated future amortization expense is as follows (in thousands):
Year Ending December 31, |
||||
Remainder of 2012 |
$ | 17,425 | ||
2013 |
22,833 | |||
2014 |
22,143 | |||
2015 |
21,692 | |||
2016 |
20,702 | |||
Thereafter |
39,497 | |||
|
|
|||
$ | 144,292 | |||
|
|
- 9 -
Table of Contents
Note 5. Accounts Payable and Accrued Expenses
Accounts payable, accrued expenses and other current liabilities as of March 31, 2012 and December 31, 2011 consist of the following (in thousands):
March 31, 2012 | December 31, 2011 | |||||||
Accounts payable |
$ | 3,732 | $ | 5,617 | ||||
Due to predecessor pension plan |
1,194 | 1,194 | ||||||
Accrued management fees |
1,167 | 742 | ||||||
Other accrued expenses |
6,737 | 7,099 | ||||||
|
|
|
|
|||||
$ | 12,830 | $ | 14,652 | |||||
|
|
|
|
Note 6. Long-Term Debt
On April 30, 2007, in conjunction with an acquisition transaction, the Company entered into a subordinated, unsecured contingent note with prior owners of one of the Companys acquired practices. The payment amount is determined by the practices cumulative EBITDA over a five-year period, with a minimum payment not to be less than $15.0 million and a maximum payment not to exceed $30.0 million. Payment amounts include a 5.5% interest rate factor, and therefore the Company recorded the contingent note in the original purchase price at its minimum payment amount, discounted by the interest rate factor of 5.5%. The original discount of $2.2 million is being amortized into interest expense over the term of the contingent note using the interest method.
On May 26, 2010, the Company entered into a $335.0 million credit facility with Barclays Bank PLC and certain other lenders. This credit facility, which is collateralized by substantially all of the Companys assets and guaranteed by all of the Companys subsidiaries, included a $225.0 million senior secured first lien term loan facility that matures May 2016. The credit facility also included a $110.0 million senior secured first lien revolving credit facility that matures May 2015, of which $50.0 million became available upon the closing of the new credit facility and $60.0 million became available on December 20, 2010, when the Company amended the credit facility and issued $200.0 million unsecured Senior Notes, as described below. The Companys term loan facility bears interest, at the Companys option, at a rate initially equal to the prime rate plus 3.25 percent per annum or LIBOR (subject to a floor of 2.00 percent) plus 4.25 percent per annum. In connection with the issuance of the $200.0 million unsecured Senior Notes, the Companys credit facility was amended and restated December 20, 2010.
The credit facility, as amended December 20, 2010, requires the Company to comply on a quarterly basis with certain financial covenants, including a senior secured leverage ratio calculation and an interest coverage ratio which become more restrictive over time. Also, on an annual basis the Company must not exceed a specified maximum amount of consolidated capital expenditures. In addition, the new term loan facility includes negative covenants restricting or limiting the Companys ability to, without prior approval of the lenders, among other things, incur, assume or permit to exist additional indebtedness or guarantees; incur liens and engage in sale leaseback transactions; make loans and investments; declare dividends, make payments or redeem or repurchase capital stock; engage in mergers, acquisitions and other business combinations; prepay, redeem or purchase certain indebtedness; amend or otherwise alter terms of its indebtedness; sell assets; enter into transactions with affiliates and alter the business it conducts. As of March 31, 2012, the Company had $5.5 million outstanding and $104.5 million available under its revolving credit facility and was in compliance with all loan covenants.
- 10 -
Table of Contents
Note 6. Long-Term Debt (Continued)
On December 20, 2010, the Company issued $200.0 million in unsecured Senior Notes that mature on January 15, 2018. The Senior Notes bear interest at an annual rate of 10.75%, which is payable each January 15 and July 15. In accordance with the Senior Notes indenture, the Company is subject to certain limitations on issuing additional debt and is required to submit quarterly and annual financial reports. The Senior Notes are redeemable at the Companys option beginning on January 15, 2015 at 105.375% of par, plus accrued interest. The redemption price decreases to 102.688% of par on January 15, 2016 and to 100% of par on January 15, 2017. Under certain circumstances, prior to January 15, 2015, the Company may at its option redeem all, but not less than all, of the notes at a redemption price equal to 100% of the principal amount of the notes, plus accrued interest and a premium as defined in the Senior Notes indenture. The Senior Notes rank equally in right of repayment with all of the Companys other senior indebtedness, but are subordinated to the Companys secured indebtedness to the extent of the value of the assets securing that indebtedness. The Company used a portion of the proceeds from the issuance of the Senior Notes to repay $110.0 million of the $224.4 million principal then owed under the term loan portion of its $335.0 million credit facility. In connection with the partial repayment, the Company recorded a non-cash charge of approximately $4.7 million for the write-off of the pro rata portion of unamortized original issue discount, prepaid administration fees, and deferred debt issue costs.
Long-term debt consists of the following as of March 31, 2012 and December 31, 2011 (in thousands):
March 31, 2012 | December 31, 2011 | |||||||
Senior Notes |
$ | 200,000 | $ | 200,000 | ||||
Term loan |
114,438 | 114,438 | ||||||
Revolver |
5,500 | | ||||||
Subordinated unsecured contingent note dated April 30, 2007 |
2,840 | 2,840 | ||||||
Capital lease obligations |
400 | 243 | ||||||
|
|
|
|
|||||
323,178 | 317,521 | |||||||
Less: |
||||||||
Original issue discount, net |
(1,187 | ) | (1,259 | ) | ||||
Current portion |
(2,935 | ) | (2,910 | ) | ||||
|
|
|
|
|||||
Long-term debt, net of current portion |
$ | 319,056 | $ | 313,352 | ||||
|
|
|
|
As of March 31, 2012, estimated future debt principal payments are as follows (in thousands):
Year Ending December 31, |
||||
Remainder of 2012 |
$ | 2,913 | ||
2013 |
106 | |||
2014 |
94 | |||
2015 |
5,560 | |||
2016 |
114,492 | |||
Thereafter |
200,013 | |||
|
|
|||
$ | 323,178 | |||
|
|
- 11 -
Table of Contents
Note 7. Related Party Transactions
Acquisition Target Consulting Agreement
On June 2, 2006, and as subsequently amended and restated on July 6, 2011, the Company and an entity owned by two members of the Company entered into a professional services agreement to provide certain acquisition target identification consulting services to the Company. In exchange for these services, the Company pays to the entity a monthly retainer of $23,000, plus reimbursable expenses. The entity also earns a success fee of $45,000 for each identified acquisition consummated by the Company. The Company paid the entity a total of $95,000 and $125,000, during the three months ended March 31, 2012 and 2011, respectively. As of March 31, 2012 and December 31, 2011, $0 and $24,000, respectively, were owed under this arrangement.
Management and Financial Advisory Agreement
On June 2, 2006, the Company, through its wholly-owned subsidiary, and two members of the Company entered into a management services agreement (the Agreement). On June 12, 2009 the Agreement was amended to substitute a new member for one of the original members. The Agreement calls for the members and their affiliates to provide certain financial and management advisory services in connection with the general business planning and forecasting and acquisition and divestiture strategies of the Company. In exchange for the services, the Company pays fees equal to 1.0% of revenues, plus expenses to the members (Management Fees).
As of March 31, 2012 and December 31, 2011, $1.2 million and $1.5 million, respectively, of these Management Fees are reflected in accounts payable and accrued expenses in the accompanying consolidated balance sheets. The consolidated condensed statement of operations includes Management Fees of $0.7 million and $0.6 million for the respective three months ended March 31, 2012 and 2011, respectively. During the three months ended March 31, 2012 and 2011, the Company paid management fees of $1.0 million and $0.6 million, respectively.
Facilities Lease Agreements
The Company currently leases six of its facilities from entities owned by physician employees or affiliated physicians who are also former owners of the acquired practices. The leases provide for monthly aggregate base payments of approximately $90,000 and expire in May and December 2012, December 2013, December 2014, April 2017 and October 2020. Rent paid to the related entities was $0.3 million and $0.3 million for the three months ended March 31, 2012 and 2011, respectively.
Note 8. Members Equity
Prior to April 1, 2011, the Company had multiple classes of membership interests, including A, A-1, B, C, X, D-1, D-2 and D-3 units. Effective as of April 1, 2011, Aurora Holdings amended and restated its operating agreement in order to reclassify its existing limited liability company units as a single class of 23,549,812 units. The reclassification did not result in a material change in the unit holders ownership of the Company on a fully-diluted basis.
During the three months ended March 31, 2012 members made contributions to the Company of $43,000.
- 12 -
Table of Contents
Note 9. Equity-Based Compensation
On July 6, 2011, the Company adopted the Aurora Diagnostics Holdings, LLC 2011 Equity Incentive Plan for the grant of options to purchase units of Aurora Holdings to eligible participants. During the quarter ended March 31, 2012, the Company granted options to purchase 376,490 units to employees and reserved the equivalent number of units for issuance upon the future exercise of awards pursuant to the plan. The weighted average fair value of these options was $4.49.
The options vest annually on each anniversary of the grant date through March 1, 2017. The Company valued the options using the Black-Scholes method with weighted average assumptions of 36% for volatility, 6.5 years for expected life and 1.3% for the risk free interest rate. Equity compensation expense, of which $133,000 was included in selling, general and administrative expenses for the three months ended March 31, 2012, are being amortized over the vesting periods through March 1, 2017. As of March 31, 2012, the total remaining unamortized equity compensation cost was approximately $5.5 million.
Note 10. Commitments and Contingencies
During the ordinary course of business, the Company has become and may in the future become subject to pending and threatened legal actions and proceedings. The Company may have liability with respect to its employees and its pathologists. Medical malpractice claims are generally covered by insurance. While the Company believes the outcome of any such pending legal actions and proceedings, individually or in the aggregate, will not have a material adverse effect on the Companys financial condition, results of operations or liquidity, if the Company is ultimately found liable under any medical malpractice claims, there can be no assurance the Companys medical malpractice insurance coverage will be adequate to cover any such liability. The Company may also, from time to time, be involved with legal actions related to the acquisition of and affiliation with physician practices, the prior conduct of such practices, or the employment (and restriction on competition) of its physicians. There can be no assurance any costs or liabilities for which the Company becomes responsible in connection with such claims or actions will not be material or will not exceed the limitations of any applicable indemnification provisions or the financial resources of the indemnifying parties.
During 2011, the Company received claims of overpayments from one payor for a total of $1.6 million. The Company intends to vigorously defend against this asserted claim; however, at this time, the ultimate outcome cannot be determined and the Company cannot reasonably estimate a potential loss in the event of an adverse opinion.
Contingent Notes
As discussed in Note 2, in connection with certain of its acquisitions, the Company agreed to pay additional consideration in future periods, based upon the attainment of stipulated levels of operating earnings by each of the acquired entities, as defined in their respective agreements. As of March 31, 2012, the total maximum future payments for contingent consideration issued in acquisitions was $56.3 million for acquisitions completed prior to January 1, 2009 and $98.6 million for acquisitions completed since January 1, 2009. Lesser amounts will be paid for earnings below the maximum level of stipulated earnings or no payments will be made if the practices do not achieve the minimum level of stipulated earnings as outlined in their respective agreements. Any future payments of contingent consideration will be accounted for as additional purchase price and increase goodwill for acquisitions completed prior to January 1, 2009 or, for acquisitions completed since January 1, 2009, will be reflected in the change in the fair value of the contingent consideration. As of March 31, 2012, the fair value of contingent consideration related to acquisitions completed since January 1, 2009 was $50.5 million.
- 13 -
Table of Contents
Note 10. Commitments and Contingencies (Continued)
Purchase Obligation
In March 2011, the Company entered into a five year non-cancelable commitment to purchase reagents and other laboratory supplies. Under this agreement, the Company must purchase approximately $0.8 million annually of reagents and other laboratory supplies through March 2016. Through March 31, 2012, the Company made purchases of approximately $1.1 million under the obligation. At March 31, 2012, the approximate total remaining purchase commitment is approximately $3.1 million.
In connection with the commitment, the vendor provided the Company with lab testing equipment, to which the Company will receive title upon fulfillment of its purchase obligations under the commitment. The company recorded the equipment and a corresponding obligation under purchase commitment for the fair market value of the equipment of $1.4 million. The remaining obligation under this purchase commitment included in other liabilities in the accompanying condensed consolidated balance sheets was $1.1 million and $1.2 million as of March 31, 2012 and December 31, 2011, respectively.
Note 11. Fair Value of Financial Instruments
Recurring Fair Value Measurements
The Companys interest rate cap agreement was included in deposits and other noncurrent assets at its fair value of approximately $0 and $7,000 as of March 31, 2012 and December 31, 2011, respectively. The interest rate cap, which was entered into in September 2010, was the Companys only derivative financial instrument. The fair value of the interest rate cap was estimated by obtaining quotations from the financial institution that is a counter party to the instrument. The LIBOR rate is observable at commonly quoted intervals over the term of these derivatives and they are therefore considered Level 2 items. The fair value is an estimate of the net amount that the Company would have to pay or would receive on that date if the agreements were canceled or transferred to other parties. During the three month periods ended March 31, 2012 and 2011, the Company recorded interest expense of $7,000 and $73,000, respectively, for the change in fair value of the interest rate cap agreement.
As of March 31, 2012 and December 31, 2011, the fair value of contingent consideration related to acquisitions since January 1, 2009 was $50.5 million and $51.7 million, respectively. The fair value of contingent consideration is derived using valuation techniques that incorporate unobservable inputs and are considered Level 3 items. We utilize a present value of estimated future payments approach to estimate the fair value of the contingent consideration. Estimates for fair value of contingent consideration primarily involve two inputs, which are i) the projections of the financial performance of the acquired practices that are used to calculate the amount of the payments and ii) the discount rates used to calculate the present value of future payments. Changes in either of these inputs will impact the estimated fair value of contingent consideration. At March 31, 2012 the discount rates ranged from 14.7 percent to 18.2 percent.
- 14 -
Table of Contents
Note 11. Fair Value of Financial Instruments (Continued)
The following is a summary of the Companys fair value instruments categorized by their fair value input level as of March 31, 2012 (in thousands):
Significant Other | Significant | |||||||||||||||
Quoted Prices | Observable | Unobservable | ||||||||||||||
in Active Markets | Inputs | Inputs | ||||||||||||||
Fair Value | Level 1 | Level 2 | Level 3 | |||||||||||||
Liabilities: |
||||||||||||||||
Current portion of fair value of contingent consideration |
$ | 20,290 | $ | | $ | | $ | 20,290 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Fair value of contingent consideration, net of current portion |
$ | 30,160 | $ | | $ | | $ | 30,160 | ||||||||
|
|
|
|
|
|
|
|
The following is a roll-forward of the Companys Level 3 fair value instruments for the three months ended March 31, 2012 (in thousands):
Beginning | Total (Gains) / | Ending | ||||||||||||||||||
Balance | Losses Realized | Balance | ||||||||||||||||||
January 1, 2012 | and Unrealized | Issuances | Settlements | March 31, 2012 | ||||||||||||||||
Fair value of contingent consideration |
$ | 51,720 | $ | 2,247 | $ | | $ | (3,517 | ) | $ | 50,450 | |||||||||
|
|
|
|
|
|
|
|
|
|
Non-Recurring Fair Value Measurements
Certain assets that are measured at fair value on a non-recurring basis, including property and equipment and intangible assets, are adjusted to fair value only when the carrying values are greater than their fair values. The Company completed its annual impairment evaluations as of September 30, 2011 and recorded a write-off of goodwill and intangibles to reflect the then current estimated fair value of the impaired reporting units. The fair value was derived with fair value models utilizing unobservable inputs that therefore are considered Level 3 items.
As of March 31, 2012 and December 31, 2011 the carrying amounts of cash, accounts receivable, accounts payable, accrued interest and accrued expenses approximate fair value based on the short maturity of these instruments. As of March 31, 2012 and December 31, 2011 the fair value of the Companys long-term debt was $321.0 million and $316.3 million, respectively. The Company uses quoted market prices and yields for the same or similar types of borrowings in active markets when available to determine the fair value of the Companys debt. These fair values are considered Level 2 items.
- 15 -
Table of Contents
Note 12. Income Taxes
The Company is a Delaware limited liability company. For federal income tax purposes, the Company is treated as a partnership. Accordingly, the Company is generally not subject to income taxes and the income attributable to the limited liability company is distributed to the members in accordance with the terms of the operating agreement. However, certain of the Companys subsidiaries are structured as corporations, file separate returns, and therefore are subject to federal and state income taxes. The provision for income taxes for these subsidiaries is reflected in the Companys condensed consolidated financial statements and includes federal and state taxes currently payable and changes in deferred tax assets and liabilities excluding the establishment of deferred tax assets and liabilities related to acquisitions.
The benefit for federal and state taxes was $465,000 and $47,000 for the three months ended March 31, 2012 and 2011, respectively. The increase in the benefit for the three months ended March 31, 2012, compared to three months ended March 31, 2011 primarily relates to the results of the Companys acquisitions in 2011 structured as corporations. Approximately $6,000 and $20,000 of the provision for the three months ended March 31, 2012 and 2011, respectively, relates to states that have a business income tax, gross receipts tax or modified gross receipts tax for partnerships.
Note 13. Guarantor Subsidiaries
The following information is presented as required by regulations of the Securities and Exchange Commission in connection with the Companys 10.75% Senior Notes due 2018. This information is not routinely prepared for use by management. The operating and investing activities of the separate legal entities included in the Companys consolidated financial statements are fully interdependent and integrated. Accordingly, consolidating the operating results of those separate legal entities is not representative of what the actual operating results of those entities would be on a stand-alone basis. Operating expenses of those separate legal entities include intercompany charges for management fees and other services. Certain expense items that are applicable to the Companys subsidiaries are typically recorded in the books and records of Aurora Diagnostics Holdings, LLC. For purposes of this footnote disclosure, such balances and amounts have been pushed down to the respective subsidiaries either on a specific identification basis, or when such items cannot be specifically attributed to an individual subsidiary, have been allocated on an incremental or proportional cost basis to Aurora Diagnostics Holdings, LLC and the Companys subsidiaries.
The following tables present consolidating financial information as of March 31, 2012 and December 31, 2011 and for the three months ended March 31, 2012 and 2011 for (i) Aurora Diagnostics Holdings, LLC, (ii) on a combined basis, the subsidiaries of the Company that are guarantors of the Companys Senior Notes (the Subsidiary Guarantors) and (iii) on a combined basis, the subsidiaries of the Company that are not guarantors of the Companys Senior Notes (the Non-Guarantor Subsidiaries). For presentation in the following tables, Subsidiary Guarantors includes revenue and expenses and assets and liabilities for those subsidiaries directly or indirectly 100% owned by the Company, including those entities that have contractual arrangements with affiliated physician groups. Essentially, all property and equipment reflected in the accompanying consolidated balance sheets collateralize the Companys debt. As such, as of both March 31, 2012 and December 31, 2011, $4.2 million of property and equipment held by Non-Guarantor Subsidiaries is reflected under Subsidiary Guarantors in the following tables.
- 16 -
Table of Contents
Note 13. Guarantor Subsidiaries (Continued)
Condensed Consolidating Balance Sheets (in thousands):
Aurora | ||||||||||||||||||||
Diagnostics | Subsidiary | Non-Guarantor | Consolidating | Consolidated | ||||||||||||||||
March 31, 2012 |
Holdings, LLC | Guarantors | Subsidiaries | Adjustments | Total | |||||||||||||||
Assets |
||||||||||||||||||||
Current Assets |
||||||||||||||||||||
Cash and cash equivalents |
$ | 3,503 | $ | 8 | $ | 1,363 | $ | | $ | 4,874 | ||||||||||
Accounts receivable, net |
| 16,516 | 19,218 | | 35,734 | |||||||||||||||
Prepaid expenses and other assets |
1,233 | 1,362 | 1,527 | | 4,122 | |||||||||||||||
Prepaid income taxes |
| 252 | 1,215 | 1,467 | ||||||||||||||||
Deferred tax assets |
| 16 | 253 | | 269 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total current assets |
4,736 | 18,154 | 23,576 | | 46,466 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Property and equipment, net |
2,062 | 10,197 | | 12,259 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Other Assets: |
||||||||||||||||||||
Intercompany receivable |
411,908 | | | (411,908 | ) | | ||||||||||||||
Deferred debt issue costs, net |
9,313 | | | | 9,313 | |||||||||||||||
Deposits and other noncurrent assets |
162 | 112 | 16 | | 290 | |||||||||||||||
Deferred tax assetsnoncurrent |
| | 3,035 | | 3,035 | |||||||||||||||
Goodwill |
| 232,848 | 149,967 | | 382,815 | |||||||||||||||
Intangible assets, net |
| 74,782 | 69,510 | | 144,292 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
421,383 | 307,742 | 222,528 | (411,908 | ) | 539,745 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
$ | 428,181 | $ | 336,093 | $ | 246,104 | $ | (411,908 | ) | $ | 598,470 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Liabilities and Members Equity |
||||||||||||||||||||
Current Liabilities |
||||||||||||||||||||
Current portion of long-term debt |
$ | 2,847 | $ | 88 | $ | | $ | | $ | 2,935 | ||||||||||
Current portion of fair value of contingent consideration |
| 11,830 | 8,460 | | 20,290 | |||||||||||||||
Accounts payable and accrued expenses |
6,424 | 2,520 | 3,886 | | 12,830 | |||||||||||||||
Accrued compensation |
3,484 | 2,946 | 2,109 | | 8,539 | |||||||||||||||
Accrued interest |
4,716 | | | | 4,716 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total current liabilities |
17,471 | 17,384 | 14,455 | | 49,310 | |||||||||||||||
Intercompany payable |
| 214,473 | 197,435 | (411,908 | ) | | ||||||||||||||
Long-term debt, net of current portion |
318,776 | 280 | | | 319,056 | |||||||||||||||
Deferred tax liabilities, net |
| 2,286 | 18,554 | | 20,840 | |||||||||||||||
Fair value of contingent consideration, net of current portion |
| 14,500 | 15,660 | | 30,160 | |||||||||||||||
Other liabilities |
1,122 | | | | 1,122 | |||||||||||||||
Members Equity |
90,812 | 87,170 | | | 177,982 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
$ | 428,181 | $ | 336,093 | $ | 246,104 | $ | (411,908 | ) | $ | 598,470 | ||||||||||
|
|
|
|
|
|
|
|
|
|
- 17 -
Table of Contents
Note 13. Guarantor Subsidiaries (Continued)
Aurora | ||||||||||||||||||||
Diagnostics | Subsidiary | Non-Guarantor | Consolidating | Consolidated | ||||||||||||||||
December 31, 2011 |
Holdings, LLC | Guarantors | Subsidiaries | Adjustments | Total | |||||||||||||||
Assets |
||||||||||||||||||||
Current Assets |
||||||||||||||||||||
Cash and cash equivalents |
$ | 14,303 | $ | 127 | $ | 1,832 | $ | | $ | 16,262 | ||||||||||
Accounts receivable, net |
| 16,319 | 18,906 | | 35,225 | |||||||||||||||
Prepaid expenses and other assets |
1,042 | 1,003 | 1,151 | | 3,196 | |||||||||||||||
Prepaid income taxes |
96 | 143 | 905 | 1,144 | ||||||||||||||||
Deferred tax assets |
| 16 | 253 | | 269 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total current assets |
15,441 | 17,608 | 23,047 | | 56,096 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Property and equipment, net |
1,977 | 10,329 | | | 12,306 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Other Assets: |
||||||||||||||||||||
Intercompany receivable |
409,233 | | | (409,233 | ) | | ||||||||||||||
Deferred debt issue costs, net |
9,944 | | | | 9,944 | |||||||||||||||
Deferred tax assetsnoncurrent |
| | 3,035 | | 3,035 | |||||||||||||||
Deposits and other noncurrent assets |
156 | 166 | 17 | | 339 | |||||||||||||||
Goodwill |
| 227,783 | 147,348 | | 375,131 | |||||||||||||||
Intangible assets, net |
| 77,937 | 72,175 | | 150,112 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
419,333 | 305,886 | 222,575 | (409,233 | ) | 538,561 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
$ | 436,751 | $ | 333,823 | $ | 245,622 | $ | (409,233 | ) | $ | 606,963 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Liabilities and Members Equity |
||||||||||||||||||||
Current Liabilities |
||||||||||||||||||||
Current portion of long-term debt |
$ | 2,847 | $ | 63 | $ | | $ | | $ | 2,910 | ||||||||||
Current portion of fair value of contingent consideration |
| 10,900 | 8,370 | | 19,270 | |||||||||||||||
Accounts payable, accrued expenses and other current liabilities |
7,875 | 3,035 | 3,742 | | 14,652 | |||||||||||||||
Accrued compensation |
4,722 | 3,947 | 3,708 | | 12,377 | |||||||||||||||
Accrued interest |
10,019 | | | | 10,019 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total current liabilities |
25,463 | 17,945 | 15,820 | | 59,228 | |||||||||||||||
Intercompany payable |
| 215,145 | 194,088 | (409,233 | ) | | ||||||||||||||
Long-term debt, net of current portion |
313,206 | 146 | | | 313,352 | |||||||||||||||
Deferred tax liabilities |
| 2,286 | 18,554 | | 20,840 | |||||||||||||||
Fair value of contingent consideration, net of current portion |
| 15,290 | 17,160 | | 32,450 | |||||||||||||||
Other liabilities |
1,203 | | | | 1,203 | |||||||||||||||
Members Equity |
96,879 | 83,011 | | | 179,890 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
$ | 436,751 | $ | 333,823 | $ | 245,622 | $ | (409,233 | ) | $ | 606,963 | ||||||||||
|
|
|
|
|
|
|
|
|
|
- 18 -
Table of Contents
Note 13. Guarantor Subsidiaries (Continued)
Condensed Consolidating Statements of Operations (in thousands):
Aurora | ||||||||||||||||
For the Three Months Ended | Diagnostics | Subsidiary | Non-Guarantor | Consolidated | ||||||||||||
March 31, 2012 |
Holdings, LLC | Guarantors | Subsidiaries | Total | ||||||||||||
Net revenue |
$ | | $ | 39,807 | $ | 32,320 | $ | 72,127 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Operating costs and expenses: |
||||||||||||||||
Cost of services |
| 15,316 | 19,874 | 35,190 | ||||||||||||
Selling, general and administrative expenses |
4,873 | 7,641 | 5,207 | 17,721 | ||||||||||||
Provision for doubtful accounts |
| 2,556 | 2,183 | 4,739 | ||||||||||||
Intangible asset amortization expense |
| 3,155 | 2,665 | 5,820 | ||||||||||||
Management fees |
(4,402 | ) | 5,456 | (325 | ) | 729 | ||||||||||
Acquisition and business development costs |
71 | | | 71 | ||||||||||||
Change in fair value of contingent consideration |
| 1,474 | 773 | 2,247 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating costs and expenses |
542 | 35,598 | 30,377 | 66,517 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Income (loss) from operations |
(542 | ) | 4,209 | 1,943 | 5,610 | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Other (expense) income: |
||||||||||||||||
Interest expense |
(5,695 | ) | (168 | ) | (2,300 | ) | (8,163 | ) | ||||||||
Other income |
| 2 | 2 | 4 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total other expense, net |
(5,695 | ) | (166 | ) | (2,298 | ) | (8,159 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Income (loss) before income taxes |
(6,237 | ) | 4,043 | (355 | ) | (2,549 | ) | |||||||||
Provision (benefit) for income taxes |
5 | (115 | ) | (355 | ) | (465 | ) | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income (loss) |
$ | (6,242 | ) | $ | 4,158 | $ | | $ | (2,084 | ) | ||||||
|
|
|
|
|
|
|
|
- 19 -
Table of Contents
Note 13. Guarantor Subsidiaries (Continued)
Aurora | ||||||||||||||||
For the Three Months Ended | Diagnostics | Subsidiary | Non-Guarantor | Consolidated | ||||||||||||
March 31, 2011 |
Holdings, LLC | Guarantors | Subsidiaries | Total | ||||||||||||
Net revenue |
$ | | $ | 36,152 | $ | 26,422 | $ | 62,574 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Operating costs and expenses: |
||||||||||||||||
Cost of services |
| 12,865 | 16,312 | 29,177 | ||||||||||||
Selling, general and administrative expenses |
3,793 | 6,707 | 4,326 | 14,826 | ||||||||||||
Provision for doubtful accounts |
| 2,377 | 1,972 | 4,349 | ||||||||||||
Intangible asset amortization expense |
| 3,177 | 2,337 | 5,514 | ||||||||||||
Management fees |
(3,374 | ) | 3,958 | 65 | 649 | |||||||||||
Acquisition and business development costs |
283 | | | 283 | ||||||||||||
Change in fair value of contingent consideration |
| 1,300 | 402 | 1,702 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating costs and expenses |
702 | 30,384 | 25,414 | 56,500 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Income (loss) from operations |
(702 | ) | 5,768 | 1,008 | 6,074 | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Other income (expense): |
||||||||||||||||
Interest expense |
(6,467 | ) | (103 | ) | (1,529 | ) | (8,099 | ) | ||||||||
Other income |
| 15 | | 15 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total other expense, net |
(6,467 | ) | (88 | ) | (1,529 | ) | (8,084 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Income (loss) before income taxes |
(7,169 | ) | 5,680 | (521 | ) | (2,010 | ) | |||||||||
Provision (benefit) for income taxes |
19 | 455 | (521 | ) | (47 | ) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income (loss) |
$ | (7,188 | ) | $ | 5,225 | $ | | $ | (1,963 | ) | ||||||
|
|
|
|
|
|
|
|
- 20 -
Table of Contents
Note 13. Guarantor Subsidiaries (Continued)
Condensed Consolidating Statements of Cash Flows (in thousands):
Aurora | ||||||||||||||||
For the Three Months Ended | Diagnostics | Subsidiary | Non-Guarantor | Consolidated | ||||||||||||
March 31, 2012 |
Holdings, LLC | Guarantors | Subsidiaries | Total | ||||||||||||
Cash Flows From Operating Activities: |
||||||||||||||||
Net (loss) income |
$ | (6,243 | ) | $ | 4,159 | $ | | $ | (2,084 | ) | ||||||
Adjustments to reconcile net loss to net cash provided by operating activities |
931 | 5,600 | 3,437 | 9,968 | ||||||||||||
Changes in assets and liabilities, net of effects of acquisitions |
(10,658 | ) | (2,797 | ) | 896 | (12,559 | ) | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net cash (used in) provided by operating activities |
(15,970 | ) | 6,962 | 4,333 | (4,675 | ) | ||||||||||
Net cash used in investing activities |
(232 | ) | (7,058 | ) | (4,802 | ) | (12,092 | ) | ||||||||
Net cash provided by (used in) financing activities |
5,402 | (23 | ) | | 5,379 | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net decrease in cash |
(10,800 | ) | (119 | ) | (469 | ) | (11,388 | ) | ||||||||
Cash and cash equivalents, beginning of period |
14,303 | 127 | 1,832 | 16,262 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Cash and cash equivalents, end of period |
$ | 3,503 | $ | 8 | $ | 1,363 | $ | 4,874 | ||||||||
|
|
|
|
|
|
|
|
Aurora | ||||||||||||||||
For the Three Months Ended | Diagnostics | Subsidiary | Non-Guarantor | Consolidated | ||||||||||||
March 31, 2011 |
Holdings, LLC | Guarantors | Subsidiaries | Total | ||||||||||||
Cash Flows From Operating Activities: |
||||||||||||||||
Net (loss) income |
$ | (7,169 | ) | $ | 5,206 | $ | | $ | (1,963 | ) | ||||||
Adjustments to reconcile net (loss) income to net cash provided by operating activities |
756 | 5,011 | 884 | 6,651 | ||||||||||||
Changes in assets and liabilities, net of effects of acquisitions |
8,666 | (5,331 | ) | 4,732 | 8,067 | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net cash provided by operating activities |
2,253 | 4,886 | 5,616 | 12,755 | ||||||||||||
Net cash used in investing activities |
(14 | ) | (4,967 | ) | (4,879 | ) | (9,860 | ) | ||||||||
Net cash used in financing activities |
(887 | ) | (16 | ) | | (903 | ) | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net increase (decrease) in cash |
1,352 | (97 | ) | 737 | 1,992 | |||||||||||
Cash and cash equivalents, beginning of period |
38,513 | 228 | 1,200 | 39,941 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Cash and cash equivalents, end of period |
$ | 39,865 | $ | 131 | $ | 1,937 | $ | 41,933 | ||||||||
|
|
|
|
|
|
|
|
- 21 -
Table of Contents
Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations. |
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included in Part I. Item 1 of this Quarterly Report on Form 10-Q. Some of the statements made in this Quarterly Report on Form 10-Q are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, or that describe our plans, goals, intentions, objectives, strategies, expectations, beliefs and assumptions, are forward-looking statements. The words believe, may, might, will, estimate, continue, anticipate, intend, expect, project, plan, objective, could, would, should and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. We caution that the forward-looking statements in this Quarterly Report on Form 10-Q are subject to a number of known and unknown risks, uncertainties and assumptions that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Factors that could contribute to these differences include, among other things:
| changes in medical treatment or reimbursement rates or utilization for our anatomic and clinical pathology markets; |
| competition for our diagnostic services, including the internalization of testing functions and technologies by our clients; |
| the failure to successfully collect for our services; |
| payor efforts to reduce utilization and reimbursement rates; |
| changes in payor regulations, policies or payor mix; |
| changes in product mix; |
| the anticipated benefits from acquisitions not being fully realized or not being realized within the expected time frames; |
| the discovery of unknown or contingent liabilities from acquired businesses; |
| the failure of our acquired assets to generate the level of expected returns; |
| disruptions or failures of our IT solutions or infrastructure; |
| the failure to adequately safeguard data; |
| loss of key executives, pathologists and technical personnel; |
| growth in demand for our services that exceeds our ability to adequately scale our infrastructure; |
| a decline in our rate of strategic or organic growth; |
- 22 -
Table of Contents
| the loss of in-network status with or our the inability to collect from health care insurers; |
| the availability of additional capital resources; |
| the failure to maintain relationships with clients, including referring physicians and hospitals, and with payors; |
| covenants in our debt agreements; |
| our substantial level of indebtedness; |
| the protection of our intellectual property; |
| general economic, business or regulatory conditions affecting the health care and diagnostic testing services industries; |
| the introduction of new or failure of old technologies, products or tests; |
| federal or state health care reform initiatives; |
| violation of, failure to comply with, or changes in federal and state laws and regulations related to, submission of claims for our services, fraud and abuse, patient privacy, corporate practice of medicine, billing arrangements for our services and environmental, health and safety; |
| attainment of licenses required to test patient specimens from certain states or the loss or suspension of licenses; |
| our inability to obtain liability insurance coverage or claims for damages in excess of our coverage; and |
| the other risks and uncertainties discussed under the heading Risk Factors in Part II, Item 1A of this Quarterly Report and in other documents filed by the Company with the Securities and Exchange Commission, including the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2011. |
Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time-to-time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or changes in our expectations, unless otherwise required by law.
- 23 -
Table of Contents
General
We are a specialized diagnostics company providing services that play a key role in the diagnosis of cancer and other diseases. Our experienced pathologists deliver comprehensive diagnostic reports of a patients condition and consult frequently with referring physicians to help determine the appropriate treatment. Our diagnostic reports often enable the early detection of disease, allowing referring physicians to make informed and timely treatment decisions that improve their patients health in a cost-effective manner. Through our pathologist-operated laboratory practices, we provide physician-based general anatomic and clinical pathology, dermatopathology, molecular diagnostic services and other esoteric testing services to physicians, hospitals, clinical laboratories and surgery centers. Our operations consist of one reportable segment.
Recent Developments
Health Care Regulatory and Reimbursement Changes
In 2010, the U.S. Congress passed and the President signed into law the Patient Protection and Affordable Care Act, or PPACA, and the Health Care and Education Affordability Reconciliation Act of 2010, or HCEARA. Together, the PPACA and HCEARA comprise a broad health care reform initiative. While this legislation did not adversely affect reimbursement for our anatomic pathology services, this legislation provides for two separate reductions in the reimbursement rates for our clinical laboratory services: a productivity adjustment (which was 1.2 percent for 2011), and an additional 1.75 percent reduction. Each of these would reduce the annual Consumer Price Index-based update that would otherwise determine our reimbursement for clinical laboratory services. For the year ended December 31, 2011, estimated Medicare revenue from clinical lab services was less than 6 percent of our total revenue. Uncertainty also exists around the extent of coverage and reimbursement for new services. This legislation also provides for increases in the number of persons covered by public and private insurance programs in the U.S. In addition, in the Middle Class Tax Relief and Job Creation Act of 2012, passed February 17, 2012, Congress mandated an additional change in the reimbursement for clinical laboratory services. It requires CMS to rebase the fee schedule to effect an additional two percent reduction in clinical laboratory fees effective 2013.
On November 1, 2011, the Centers for Medicare & Medicaid Services (CMS) issued its 2012 Physician Fee Schedule Final Rule, which we refer to as the Final Rule. In the Final Rule, CMS instituted a reduction of approximately 27.4 percent in the conversion factor that is used to calculate physician reimbursement. This cut was scheduled to become effective as of January 1, 2012; however, Congress took actions to delay the implementation of these reductions through December 31, 2012. The Sustainable Growth Rate (SGR) formula, which is used to calculate the fee schedule conversion factor, was used again to calculate the 2012 Medicare physician fee schedule, resulting in scheduled reimbursement cuts of 27 percent. However, on December 23, 2011, Congress took action to delay the implementation of these reductions through February 29, 2012. Once again, before that implementation delay expired on February 29, 2012, Congress passed legislation late in February that prevents the implementation of these scheduled reductions and continues current payment rates for an additional 10 months, through December 31, 2012. For the year ended December 31, 2011, revenue from Medicares Physician Fee Schedule, based upon cash collections, was approximately 25 percent of our total revenue.
In addition, the Final Rule included a reduction of certain relative value units and geographic adjustment factors used to determine reimbursement for a number of our most commonly used pathology codes, including 88305, our most common code. We estimate, based on the current mix and volume of the services we provide, that this reduction could reduce our Medicare reimbursement by 3.5 percent to 4.5 percent in 2012.
Also, under Medicare regulations, we are sometimes required to bill other entities for the services that we provide. In 1999, Medicare announced a policy that applies to anatomic pathology specimens for hospital patients. This policy would require us to bill the technical component to the hospital and the professional component to Medicare for all anatomic pathology services that we provide to hospital patients. However, in 2000, the U.S. Congress prevented this policy from going into effect for all covered hospitals, which were those hospitals that had arrangements with independent laboratories in effect as of July 22, 1999, the date that CMS had first announced the policy. That grandfather provision was originally scheduled to be effective for two years, but it has been extended repeatedly by the U.S. Congress. However, in the recently passed Middle Class Tax Relief and Job Creation Act of 2012, Congress eliminated the grandfather provision beginning with dates of service of July 1, 2012. We estimate our current annualized revenue associated with the grandfather provision to be approximately $2.8 million. Therefore, we will need to negotiate with our hospitals to receive payment for these services effective July 1, 2012, and we expect that the ultimate amount that we will collect from these hospitals, although not known, will be less than the current amounts.
- 24 -
Table of Contents
In addition, in the Final Rule, CMS requested that the American Medical Associations RVS Update Committee (RUC) reexamine the relative value units (RVUs) for certain common pathology codes, including CPT 88305, which is the most common code for which we bill. RVUs are used to calculate physician reimbursement, and a reduction in the RVUs for common pathology codes could result in a reduction in physician reimbursement and have a negative impact on our business and results of operations. We do not know at this time what action the RUC will recommend after reviewing these codes.
The Budget Control Act of 2011 created a Joint Select Committee on Deficit Reduction, which was tasked with recommending proposals to reduce spending. Under the law, the Joint Committees failure to achieve a targeted deficit reduction, or Congress failure to pass the Committees recommendations without amendment by December 23, 2011, would result in automatic across-the-board cuts to most discretionary programs. Automatic cuts also would be made to Medicare and would result in aggregate reductions in Medicare payments to providers of up to two percent per fiscal year, starting in 2013 and continuing through 2021. Because the Joint Committee was not able to agree on a set of deficit reduction recommendations for Congress to vote on, cuts are scheduled beginning in the 2013, unless Congress acts to undo or delay the sequestration.
Operating Agreement and Equity Incentive Plan
Effective April 1, 2011, Aurora Holdings amended and restated its operating agreement in order to reclassify its existing limited liability company units as a single class of units. The reclassification did not result in a material change in the unit holders ownership of the Company on a fully-diluted basis.
On July 6, 2011, we adopted the Aurora Diagnostics Holdings, LLC 2011 Equity Incentive Plan for the grant, from time to time, to eligible participants of options to purchase units of Aurora Holdings. During the quarter ended March 31, 2012, we granted options to purchase 376,490 units to employees and reserved the equivalent number of units for issuance upon the future exercise of awards pursuant to the plan.
2011 Acquisitions
During 2011, we acquired four pathology practices. On January 1, 2011, we acquired 100 percent of the equity of two pathology practices for an aggregate cash purchase price of $36.9 million. These acquisitions were consummated on January 1, 2011 and, therefore, the cash paid totaling $36.9 million was included in deposits and other non-current assets as of December 31, 2010. On June 2, 2011, we acquired 100 percent of the equity of a third pathology practice for a cash purchase price of $14.7 million. On August 1, 2011, we acquired substantially all of the assets of a fourth pathology practice for an aggregate cash purchase price of $26.5 million. Each of the transactions included contingent consideration payable over three to five years based on the acquired practices future performance. We have estimated the fair value of the contingent consideration and recorded a related liability as of the date of acquisition. At the date of acquisition, the maximum amount of the contingent consideration, assuming the acquisitions meet the maximum stipulated earnings level, was $53.2 million payable over three to five years.
As a result of the acquisitions completed in 2011, many of the changes in our consolidated results of operations and financial position discussed below relate to acquisitions.
- 25 -
Table of Contents
Results of Operations
The following table outlines our results of operations as a percentage of net revenue for the three month periods ended March 31, 2012 and 2011.
2012 | 2011 | |||||||
Net revenue |
100.0 | % | 100.0 | % | ||||
|
|
|
|
|||||
Operating costs and expenses: |
||||||||
Cost of services |
48.8 | % | 46.6 | % | ||||
Selling, general and administrative expenses |
24.6 | % | 23.7 | % | ||||
Provision for doubtful accounts |
6.6 | % | 7.0 | % | ||||
Intangible asset amortization expense |
8.1 | % | 8.8 | % | ||||
Management fees |
1.0 | % | 1.0 | % | ||||
Acquisition and business development costs |
0.1 | % | 0.5 | % | ||||
Change in fair value of contingent consideration |
3.1 | % | 2.7 | % | ||||
|
|
|
|
|||||
Total operating costs and expenses |
92.2 | % | 90.3 | % | ||||
|
|
|
|
|||||
Income from operations |
7.8 | % | 9.7 | % | ||||
|
|
|
|
|||||
Other income (expense): |
||||||||
Interest expense |
-11.3 | % | -12.9 | % | ||||
Other income |
0.0 | % | 0.0 | % | ||||
|
|
|
|
|||||
Total other expense, net |
-11.3 | % | -12.9 | % | ||||
|
|
|
|
|||||
Loss before income taxes |
-3.5 | % | -3.2 | % | ||||
Benefit for income taxes |
-0.6 | % | -0.1 | % | ||||
|
|
|
|
|||||
Net loss |
-2.9 | % | -3.1 | % | ||||
|
|
|
|
Our historical consolidated operating results do not reflect the results of operations of our acquisitions prior to the effective date of those acquisitions. As a result, our historical consolidated operating results may not be indicative of what our results of operations will be for future periods.
Comparison of the Three Months Ended March 31, 2012 and 2011
Net revenue
Net revenue increased approximately $9.5 million, or 15.3 percent, to $72.1 million for the quarter ended March 31, 2012, from $62.6 million for the quarter ended March 31, 2011. Organic revenue increased approximately $2.2 million, or 3.5 percent, from $62.6 million to $64.8 million, while the acquisitions completed after January 1, 2011 added approximately $7.3 million of net revenue.
Total accessions grew by approximately 56,000, or 10.3 percent, to 598,000 for the quarter ended March 31, 2012, compared to 542,000 for the quarter ended March 31, 2011. Organic accessions grew by 6,000, or 1.1%, to 548,000 for the quarter ended March 31, 2012 compared to approximately 542,000 for the quarter ended March 31, 2011, while the acquisitions completed after January 1, 2011 added approximately 50,000 accessions. The average revenue per accession for organic accessions for the quarter ended March 31, 2012 was approximately $118, up from $116 in the quarter ended March 31, 2011. The increase in organic average revenue per accession compared to same quarter in 2011 was due primarily to a change in service mix, with a higher percentage of anatomic pathology accessions and lower percentage of clinical pathology accessions.
- 26 -
Table of Contents
We expect the average revenue per accession of our organic business to fluctuate primarily as the result of changes in service mix, including the conversion of more global fee arrangements to TC or PC arrangements and further growth in womens health pathology services, which should result in an increase of the number of clinical tests. Womens health services and clinical tests generally have lower revenue per accession and, therefore, may decrease slightly our average revenue per accession. In addition, our growth rates and average revenue per accession may be positively or negatively impacted by the reimbursement market and the service mix and average revenue per accession of acquisitions completed in the future.
For the quarters ended March 31, 2012 and 2011, our pathology diagnostic testing services accounted for substantially all of our revenue.
Cost of services
Cost of services increased approximately $6.0 million, or 20.6 percent, to $35.2 million for the quarter ended March 31, 2012 from $29.2 million for the quarter ended March 31, 2011. Of the total increase, $2.9 million related to the acquisitions completed after January 1, 2011 and the remaining $3.1 million related to our existing business. The increase in costs of services for our existing business included $1.8 million for higher wages and salaries and payroll related costs primarily related to increased headcount and $0.9 million for increased technical processing costs primarily related to growth in accessions, particularly in molecular, histology and cytology. In addition, equipment related costs increased by $0.2 million related to purchases of lab and office equipment and distribution costs increased by $0.2 million related primarily to additional routes.
As a percentage of net revenue, cost of services was 48.8 percent and 46.6 percent for the quarters ended March 31, 2012 and 2011, respectively, and our gross margins were 51.2 percent and 53.4 percent for the quarters ended March 31, 2012 and 2011, respectively. We currently anticipate that our gross margin will decline slightly due to a combination of lower average revenue per accession, increased costs related to pathologist retention and replacement and higher costs and lower gross margins in our womens health pathology services, including clinical tests. Cost of services and our related gross profit percentages may be positively or negatively impacted by the market, service mix and unit price dynamics of acquisitions completed in the future.
Selling, general and administrative expenses
Selling, general and administrative expenses increased approximately $2.9 million, or 19.5 percent, to $17.7 million for the quarter ended March 31, 2012 from $14.8 million for the quarter ended March 31, 2011. Of the total increase, $1.2 million related to acquisitions, $0.6 million related to the labs we have operated for two full comparable quarters and $1.1 million related to corporate expenses. Higher costs at our existing business were primarily for sales and marketing costs, including sales commissions and costs associated with client electronic medical records systems and interfaces. The increase in corporate selling, general and administrative costs primarily related to the addition of personnel in information technology (IT), marketing, finance and managed care to support growth, as well as severance, partially offset by lower expense related to our performance incentive programs for corporate staff. The increased corporate expenses also included $0.1 million of non-cash equity compensation expense for options granted under the Aurora Diagnostics Holdings, LLC 2011 Equity Incentive Plan adopted on July 6, 2011.
As a percentage of net revenue, selling, general and administrative expenses were 24.6 percent and 23.7 percent for the quarters ended March 31, 2012 and 2011, respectively. We expect to make additional investments in selling, general and administrative expenses in 2012, including the addition of field sales representatives and marketing personnel, managed care support and IT personnel. In addition, we expect accounting, legal, compliance and other related costs to increase due to public company costs, including compliance with the Sarbanes-Oxley Act, and costs to convert laboratory and billing systems.
- 27 -
Table of Contents
Provision for doubtful accounts
Our provision for doubtful accounts increased approximately $0.4 million, or 9.0 percent, to $4.7 million for the quarter ended March 31, 2012, from $4.3 million for the quarter ended March 31, 2011. The increase in the provision for doubtful accounts related to the acquisitions completed after January 1, 2011 and the labs we have operated for full comparable quarters was relatively unchanged. As a percentage of net revenue, the provision for doubtful accounts was 6.6 percent for the quarter ended March 31, 2012, compared to 7.0 percent for the quarter ended March 31, 2011. The provision for doubtful accounts for labs operated for full comparable quarters was 6.7 percent for the quarter ended March 31, 2012 compared to 7.0% for the quarter ended March 31, 2011.
We expect our consolidated provision for doubtful accounts to range between 6.5 percent and 7.5 percent in future. The Companys consolidated provision for doubtful accounts could be positively or negatively impacted by the provision for doubtful accounts for laboratories that we acquire in the future.
Intangible asset amortization expense (Amortization)
Amortization expense increased to $5.8 million for the quarter ended March 31, 2012, from $5.5 million for the quarter ended March 31, 2011, as a result of increases in our amortizable intangible assets associated with the acquisitions completed after January 1, 2011, partially offset by lower amortization for impaired assets. We generally amortize our intangible assets over lives ranging from 4 to 18 years.
Management fees
Management fees increased approximately $0.1 million, or 12.3 percent, to $0.7 million for the quarter ended March 31, 2012, compared to $0.6 million for the quarter ended March 31, 2011. Management fees are based on 1.0 percent of net revenue plus expenses. The majority of the increase relates to the increase in our net revenue.
Acquisition and business development costs
Transaction costs associated with our completed acquisitions and business development costs related to our prospecting and unsuccessful acquisition activity amounted to $0.1 million for the quarter ended March 31, 2012, compared to $0.3 million for the quarter ended March 31, 2011.
Change in fair value of contingent consideration
For the quarters ended March 31, 2012 and 2011, we recorded non-cash charges of $2.2 million and $1.7 million, respectively, to recognize increases in the estimated fair value of contingent consideration issued in connection with our acquisitions completed after January 1, 2009. These increases relate to changes from the original estimate of the fair value, including numerous variables such as the discount rate, remaining pay out period and the projected performance for each acquisition.
Interest expense
Interest expense increased approximately $0.1 million, or 0.8 percent, to $8.2 million for the quarter ended March 31, 2012, from $8.1 million for the quarter ended March 31, 2011. The increase in interest expense was primarily due to interest expense related to amounts drawn under our revolving credit facility during the first quarter of 2012. For the quarter ended March 31, 2012 our average debt balance was $321.9 million at an effective rate of 10.17 percent, compared to an average debt balance of $320.4 million and an effective rate of 10.25 percent for the same period in 2011.
Provision for income taxes
We are a Delaware limited liability company for federal and state income tax purposes, in accordance with the applicable provisions of the Internal Revenue Code. Accordingly, we generally have not been subject to income taxes, and the income attributable to us has been allocated to the members of Aurora Holdings in accordance with the terms of the Aurora Holdings LLC Agreement. We have made tax distributions to the members in amounts designed to provide such members with sufficient cash to pay taxes on their allocated income. However, certain of our subsidiaries are structured as corporations and therefore are subject to federal and state income taxes. The benefit for federal and state income taxes for these subsidiaries, as reflected in our condensed consolidated financial statements amounted to $0.5 million and $47,000 for the quarters ended March 31, 2012 and 2011, respectively.
- 28 -
Table of Contents
Liquidity and Capital Resources
Since inception, we have primarily financed operations through capital contributions from our equityholders, long term debt financing and cash flow from operations. On May 26, 2010, we entered into a senior secured credit facility of $335.0 million with Barclays Bank PLC and certain other lenders. Our senior secured credit facility included a six-year $225.0 million senior secured term loan due in May 2016, which we refer to as the Term Loan, and a $110.0 million senior secured revolving credit facility that matures May 2015, which we refer to as the Revolver, of which $50.0 million became available immediately upon the closing of the credit facility and of which $60.0 million became available on December 20, 2010, when we amended the credit facility and issued the Senior Notes, as described below. This facility bears interest, at our option, at a rate initially equal to the prime rate plus 3.25 percent per annum or LIBOR (subject to a floor of 2.00 percent) plus 4.25 percent per annum. Proceeds from the senior secured credit facility were primarily used to repay all amounts outstanding under the credit facilities we entered into in December 2007.
On December 20, 2010, we issued $200.0 million in unsecured senior notes that mature on January 15, 2018, which we refer to as the Senior Notes. The Senior Notes bear interest at an annual rate of 10.75%, which is payable each January 15 and July 15. The first payment was made on July 15, 2011. In accordance with the indenture governing the Senior Notes, we are subject to certain limitations on issuing additional debt and are required to submit quarterly and annual financial reports to the holders of our Senior Notes. The Senior Notes are redeemable at our option beginning on January 15, 2015 at 105.375% of par, plus accrued interest. The redemption price decreases to 102.688% of par on January 15, 2016 and to 100% of par on January 15, 2017. Under certain circumstances, prior to January 15, 2015, we may at our option redeem all, but not less than all, of the Senior Notes at a redemption price equal to 100% of the principal amount of the Senior Notes, plus accrued interest and a premium as defined in the Senior Notes indenture. The Senior Notes rank equally in right of repayment with all of our other senior indebtedness but are subordinated to our secured indebtedness to the extent of the value of the assets securing that indebtedness.
On December 20, 2010, in connection with the closing of our Senior Notes offering, we amended our senior secured credit facility and applied $129.0 million of the net proceeds that we received from the offering to repay $19.0 million in principal owed under our amended and restated Revolver and $110.0 million of the $224.4 million principal then owed under our amended and restated Term Loan. As of March 31, 2012, we had $114.4 million outstanding under the amended and restated Term Loan. As of March 31, 2012, we had $5.5 million outstanding and $104.5 million available under the amended and restated Revolver.
On April 30, 2007, in conjunction with an acquisition transaction, we entered into a subordinated, unsecured contingent note with prior owners of one of our acquired practices. The payment amount is determined by the practices cumulative EBITDA over a five-year period, with a minimum payment not to be less than $15.0 million and a maximum payment not to exceed $30.0 million. Payment amounts include a 5.5 percent interest rate factor, and therefore we recorded the contingent note in the original purchase price at its minimum payment amount, discounted by the interest rate factor of 5.5 percent. The original discount of $2.2 million is being amortized into interest expense over the term of the contingent note using the effective interest rate method.
- 29 -
Table of Contents
Contingent consideration for acquisitions prior to January 1, 2009
In connection with the majority of our acquisitions, we have agreed to pay additional consideration annually over future periods of three to five years, based upon the attainment of stipulated levels of operating earnings by each of the acquired entities, as defined in their respective agreements. For acquisitions prior to January 1, 2009, we do not accrue contingent consideration obligations prior to the attainment of the objectives and the amount owed becomes fixed and determinable and is agreed to by the sellers. For the quarters ended March 31, 2012 and 2011, we paid consideration under contingent notes of $7.7 million and $9.2 million, respectively, related to acquisitions prior to January 1, 2009, resulting in the recognition of additional goodwill.
Assuming the practices acquired prior to January 1, 2009 achieve future annual operating earnings consistent with the most recent annual periods for the respective practices, contingent note payments for these acquisitions prior to January 1, 2009 would be approximately $0.7 million for the remainder of 2012 and $7.7 million for 2013. As of March 31, 2012, assuming the practices acquired prior to January 1, 2009 achieve the cumulative maximum level of operating earnings stipulated over the full term of the agreement, the potential maximum principal amount of contingent consideration payable over the next two years is approximately $56.3 million. Lesser amounts will be paid for earnings below the maximum level of stipulated earnings or no payments will be made if the practices do not achieve the minimum level of stipulated earnings as outlined in their respective agreements. Any future payments of contingent consideration for acquisitions completed prior to January 1, 2009 would be accounted for as additional purchase price and increase goodwill.
Contingent consideration for acquisitions subsequent to January 1, 2009
We utilize a present value of estimated future payments approach to estimate the fair value of the contingent consideration. These estimates involve significant projections regarding future performance of the acquired practices. If actual future results differ significantly from current estimates, the actual payments for contingent consideration will differ correspondingly. As of March 31, 2012, the fair value of contingent consideration related to the 2009, 2010 and 2011 acquisitions was $50.5 million, representing the present value of approximately $61.4 million in estimated future payments over the next three to five years. For practices acquired since January 1, 2009, the potential maximum principal amount of contingent consideration payable over the next three to five years is $98.6 million. Lesser amounts will be paid for earnings below the maximum level of stipulated earnings or no payments will be made if the practices do not achieve the minimum level of stipulated earnings as outlined in their respective agreements. For acquisitions completed since January 1, 2009, future payments will be reflected in the change in the fair value of the contingent consideration.
Cash and Working Capital
As of March 31, 2012, we have cash and cash equivalents of $4.9 million. Our primary uses of cash are to fund our operations, service debt including contingent notes, make acquisitions and purchase property and equipment. Cash used to fund our operations excludes the impact of non-cash items, such as the allowance for doubtful accounts, depreciation, impairments of goodwill and other intangible assets, changes in the fair value of the contingent consideration and non-cash stock-based compensation, and is impacted by the timing of our payments of accounts payable and accrued expenses and collections of accounts receivable.
As of March 31, 2012, we had negative working capital of $2.8 million. We believe our current cash and cash equivalents, together with cash from operations and the amount available under our amended and restated Revolver, will be sufficient to fund our capital requirements through 2013.
- 30 -
Table of Contents
Cash flows for operating activities
Net cash used in operating activities during the three months ended March 31, 2012 was $4.7 million compared to net cash provided by operating activities of $12.8 million for the three months ended March 31, 2011. Net cash used in operating activities for the three months ended March 31, 2012 reflected a net loss of $2.1 million and certain adjustments for non-cash items, including $7.0 million of depreciation and amortization, $0.6 million of amortization of original issue discount and debt issue costs, $0.1 million of equity compensation costs and a $2.2 million non-cash charge for the change in fair value of contingent consideration. Net cash used in operating activities for the three months ended March 31, 2012 also reflected increases and decreases in working capital, including a $0.5 million increase in accounts receivable, a $0.9 million increase in prepaid expenses, a $0.3 million increase in prepaid income taxes, a $5.3 million decrease in accrued interest primarily related to the interest payment on our Senior Notes, a $3.8 million decrease in accrued compensation and a $1.7 million decrease in accounts payable, accrued expenses and other current liabilities. As of March 31, 2012 our DSO (Days Sales Outstanding) was 45 days, which is up from 43 days as of December 31, 2011.
Cash flows for investing activities
Net cash used in investing activities during the three months ended March 31, 2012 was $12.1 million compared to $9.9 million during the three months ended March 31, 2011. Net cash used in investing activities during the three months ended March 31, 2012 consisted of $0.9 million of purchases of property and equipment and $11.2 million for the payment of contingent notes, including $7.7 million related to acquisitions completed prior to January 1, 2009.
Cash flows for financing activities
Net cash provided by financing activities for the three months ended March 31, 2012 was $5.4 million compared to net cash used in financing activities of $0.9 million for the three months ended March 31, 2011. For the three months ended March 31, 2012, we had net borrowings under our Revolver of $5.5 million and paid approximately $0.1 million of debt issue costs.
Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)
Adjusted EBITDA is defined as earnings before interest, taxes, depreciation and amortization (EBITDA), further adjusted to exclude unusual items and other cash or non-cash adjustments. We believe that disclosing Adjusted EBITDA provides additional information to investors, enhancing their understanding of our financial performance and providing them an important financial metric used to evaluate performance in the health care industry. Our amended senior secured credit facility contains financial covenants measured against Adjusted EBITDA. Our definition and calculation of Adjusted EBITDA for use in this report is consistent with the definition and calculation contained in our amended senior secured credit facility and the indenture governing our Senior Notes.
Adjusted EBITDA does not represent net income or cash flow from operations as those terms are defined by GAAP and does not necessarily indicate whether cash flows will be sufficient to fund cash needs. As a result, the measure can be disproportionately affected by a particularly strong or weak quarter. Further, it may not be comparable to the measure for any subsequent period or any complete fiscal year.
Adjusted EBITDA is not a recognized measurement under GAAP and should not be considered as a substitute for measures of our financial performance as determined in accordance with GAAP, such as net income and operating income. Because other companies may calculate Adjusted EBITDA differently than we do, Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. Adjusted EBITDA has other limitations as an analytical tool when compared to the use of net income, which we believe is the most directly comparable GAAP financial measure, including:
| Adjusted EBITDA does not reflect the provision of income tax expense in our various jurisdictions; |
| Adjusted EBITDA does not reflect the interest expense we incur; |
| Adjusted EBITDA does not reflect any attribution of costs to our operations related to our investments and capital expenditures through depreciation and amortization charges; |
- 31 -
Table of Contents
| Adjusted EBITDA does not reflect the cost of compensation we provide to our employees in the form of stock option awards; and |
| Adjusted EBITDA excludes expenses that we believe are unusual or non-recurring, but which others may believe are normal expenses for the operation of a business. |
The following is a reconciliation of net loss to Adjusted EBITDA (in thousands):
Three Months Ended March 31, | ||||||||
2012 (D) | 2011 (D) | |||||||
Net loss |
$ | (2,084 | ) | $ | (1,963 | ) | ||
Interest expense, net |
8,163 | 8,099 | ||||||
Income tax provision |
(465 | ) | (47 | ) | ||||
Depreciation and amortization |
6,990 | 6,433 | ||||||
|
|
|
|
|||||
EBITDA |
12,604 | 12,522 | ||||||
Management fees (A) |
729 | 649 | ||||||
Change in fair value of contingent consideration (B) |
2,247 | 1,702 | ||||||
Other charges (C) |
204 | 283 | ||||||
Other |
(4 | ) | (15 | ) | ||||
|
|
|
|
|||||
Adjusted EBITDA, as defined |
$ | 15,780 | $ | 15,141 | ||||
|
|
|
|
(A) | In accordance with our amended senior secured credit facility and the indenture governing our Senior Notes, management fees payable to affiliates are excluded from Adjusted EBITDA. |
(B) | We recorded $2.2 million and $1.7 million of non-cash charges for the three months ended March 31, 2012 and 2011, respectively, related to an increase in the estimated fair value of contingent consideration issued in connection with our acquisitions completed after January 1, 2009. These charges relate to changes from the previous estimate of the fair value, including changes in numerous variables such as the discount rate, remaining pay out period and the projected performance for each acquisition. |
(C) | Other charges include add-backs for equity based compensation and acquisition and business development costs as reported in our consolidated statements of operations. |
(D) | Adjusted EBITDA for the three months ended March 31, 2011 excludes the results of operations of acquisitions completed in 2011 prior to their acquisition date. For purposes of calculating compliance ratios for our amended senior secured credit facility, Adjusted EBITDA for the three months ended March 31, 2011 would have included approximately $2.1 million of additional Adjusted EBITDA related to operations of our 2011 acquisitions as if they were all acquired on January 1, 2011. |
For purposes of calculating compliance ratios for our amended senior secured credit facility, Adjusted EBITDA for the three months ended March 31, 2012 would have also included an additional $0.5 million related to the add-back of certain costs as permitted by the credit agreement.
Off-Balance Sheet Arrangements
The Company does not have any off-balance sheet arrangements.
- 32 -
Table of Contents
Item 3. | Quantitative and Qualitative Disclosures About Market Risk. |
Our exposure to market risks results primarily from fluctuations in interest rates. There have been no material changes to our exposure to market risks from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act) that are designed to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commissions rules and forms, and that such information is accumulated and communicated to the Companys management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. The Companys management, with the participation of the Companys principal executive officer and principal financial officer, has evaluated the effectiveness of the Companys disclosure controls and procedures as of March 31, 2012. Based on that evaluation, the principal executive officer and principal financial officer of the Company have concluded that, as of March 31, 2012, such disclosure controls and procedures were effective.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
Our disclosure controls and procedures include components of our internal control over financial reporting. Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that we will detect all control issues and instances of fraud, if any exist.
- 33 -
Table of Contents
Item 1. | Legal Proceedings. |
We are from time to time, involved in litigation that we consider to be ordinary and incidental to our business.We may be named in various claims, disputes, legal actions and other proceedings involving malpractice, employment and other matters. A negative outcome in certain of the ongoing litigation could harm our business, financial condition, liquidity or results of operations. Further, prolonged litigation, regardless of which party prevails, could be costly, divert managements attention or result in increased costs of doing business. While the outcome of pending legal actions cannot be predicted with certainty, we believe the outcome of these proceedings will not have a material adverse effect on our consolidated financial position, results of operations or liquidity.
In addition to the other information set forth in this report, you should carefully consider the factors discussed in the Risk Factors section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, which could materially affect our business, financial condition, or results of operations. The risks described in our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the fiscal year ended December 31, 2011 and in this Quarterly Report are not the only risks that we face. In addition, risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or results of operations. There have been no material changes in or additions to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.
31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended. * | |
31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended. * | |
32.1 | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ** | |
32.2 | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ** | |
101.INS | XBRL Instance Document ** | |
101.SCH | XBRL Taxonomy Extension Schema Document ** | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document ** | |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document ** | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document ** |
* | Filed herewith |
** | Furnished herewith |
Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections
- 34 -
Table of Contents
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AURORA DIAGNOSTICS HOLDINGS, LLC | ||||||
Date: May 14, 2012 | By: | /s/ Gregory A. Marsh | ||||
Gregory A. Marsh | ||||||
Chief Financial Officer (Principal Financial Officer and Duly Authorized Officer) |
- 35 -
Table of Contents
INDEX OF EXHIBITS
31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended. * | |
31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended. * | |
32.1 | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ** | |
32.2 | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ** | |
101.INS | XBRL Instance Document ** | |
101.SCH | XBRL Taxonomy Extension Schema Document ** | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document ** | |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document ** | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document ** |
* | Filed herewith |
** | Furnished herewith |
- 36 -